This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ivshina, A. V. Articles by Miller, L. D. Search for Related Content PubMed PubMed Citation Articles by Ivshina, A. V. Articles by Miller, L. D.

Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer

¹ Genome Institute of Singapore; ² Department of Haematology-Oncology, National University Hospital; Departments of ³ Pathology and ⁴ Medicine, National University of Singapore, Singapore; ⁵ Russian Computer Center, Russian Academy of Sciences, Moscow, Russia; ⁶ Department of Oncology and Pathology, Radiumhemmet, Karolinska Institute and Hospital; ⁷ Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; and ⁸ Department of Pathology, Akademiska sjukhuset, University of Uppsala, Uppsala, Sweden

Requests for reprints: Lance D. Miller, Genome Institute of Singapore, Genome Building 02-01, 60 Biopolis Street, Singapore 13872, Singapore. Phone: 65-6478-8100; Fax: 65-6478-9060; E-mail: MillerL{at}gis.a-star.edu.sg and Vladimir A. Kuznetsov, Genome Institute of Singapore, Genome Building 02-01, 60 Biopolis Street, Singapore 13872, Singapore. Phone: 65-6478-8198; Fax: 65-6478-9058; E-mail: kuznetsov{at}gis.a-star.edu.sg.

Histologic grading of breast cancer defines morphologic subtypes informative of metastatic potential, although not without considerable interobserver disagreement and clinical heterogeneity particularly among the moderately differentiated grade 2 (G2) tumors. We posited that a gene expression signature capable of discerning tumors of grade 1 (G1) and grade 3 (G3) histology might provide a more objective measure of grade with prognostic benefit for patients with G2 disease. To this end, we studied the expression profiles of 347 primary invasive breast tumors analyzed on Affymetrix microarrays. Using class prediction algorithms, we identified 264 robust grade-associated markers, six of which could accurately classify G1 and G3 tumors, and separate G2 tumors into two highly discriminant classes (termed G2a and G2b genetic grades) with patient survival outcomes highly similar to those with G1 and G3 histology, respectively. Statistical analysis of conventional clinical variables further distinguished G2a and G2b subtypes from each other, but also from histologic G1 and G3 tumors. In multivariate analyses, genetic grade was consistently found to be an independent prognostic indicator of disease recurrence comparable with that of lymph node status and tumor size. When incorporated into the Nottingham prognostic index, genetic grade enhanced detection of patients with less harmful tumors, likely to benefit little from adjuvant therapy. Our findings show that a genetic grade signature can improve prognosis and therapeutic planning for breast cancer patients, and support the view that low- and high-grade disease, as defined genetically, reflect independent pathobiological entities rather than a continuum of cancer progression. (Cancer Res 2006; 66(21): 10292-301)

This article has been cited by other articles:

				T. A. DiMeo, K. Anderson, P. Phadke, C. Feng, C. M. Perou, S. Naber, and C. Kuperwasser A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer Cancer Res., July 1, 2009; 69(13): 5364 - 5373. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 Ann. Onc., June 17, 2009; (2009) mdp322v1. [Abstract] [Full Text] [PDF]

				M. Lupien, J. Eeckhoute, C. A. Meyer, S. A. Krum, D. R. Rhodes, X. S. Liu, and M. Brown Coactivator Function Defines the Active Estrogen Receptor Alpha Cistrome Mol. Cell. Biol., June 15, 2009; 29(12): 3413 - 3423. [Abstract] [Full Text] [PDF]

				A. K. Sood, J. Wang, P. Mhawech-Fauceglia, B. Jana, P. Liang, and J. Geradts Sam-Pointed Domain Containing Ets Transcription Factor in Luminal Breast Cancer Pathogenesis Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1899 - 1903. [Abstract] [Full Text] [PDF]

				K. Liu, N. Bellam, H.-Y. Lin, B. Wang, C. R. Stockard, W. E. Grizzle, and W.-C. Lin Regulation of p53 by TopBP1: a Potential Mechanism for p53 Inactivation in Cancer Mol. Cell. Biol., May 15, 2009; 29(10): 2673 - 2693. [Abstract] [Full Text] [PDF]

				M. Mannefeld, E. Klassen, and S. Gaubatz B-MYB Is Required for Recovery from the DNA Damage-Induced G2 Checkpoint in p53 Mutant Cells Cancer Res., May 1, 2009; 69(9): 4073 - 4080. [Abstract] [Full Text] [PDF]

				R. Meyer, V. Fofanov, AnilK. Panigrahi, F. Merchant, N. Zhang, and D. Pati Overexpression and Mislocalization of the Chromosomal Segregation Protein Separase in Multiple Human Cancers Clin. Cancer Res., April 15, 2009; 15(8): 2703 - 2710. [Abstract] [Full Text] [PDF]

				J. S. Parker, M. Mullins, M. C.U. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes J. Clin. Oncol., March 10, 2009; 27(8): 1160 - 1167. [Abstract] [Full Text] [PDF]

				C. Sotiriou and L. Pusztai Gene-Expression Signatures in Breast Cancer N. Engl. J. Med., February 19, 2009; 360(8): 790 - 800. [Full Text] [PDF]

				J. Bergh Quo Vadis With Targeted Drugs in the 21st Century? J. Clin. Oncol., January 1, 2009; 27(1): 2 - 5. [Full Text] [PDF]

				L. Lukes, N. P.S. Crawford, R. Walker, and K. W. Hunter The Origins of Breast Cancer Prognostic Gene Expression Profiles Cancer Res., January 1, 2009; 69(1): 310 - 318. [Abstract] [Full Text] [PDF]

				W. M. Merritt, Y. G. Lin, L. Y. Han, A. A. Kamat, W. A. Spannuth, R. Schmandt, D. Urbauer, L. A. Pennacchio, J.-F. Cheng, A. M. Nick, et al. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer N. Engl. J. Med., December 18, 2008; 359(25): 2641 - 2650. [Abstract] [Full Text] [PDF]

				R. L. Balleine, L. R. Webster, S. Davis, E. L. Salisbury, J. P. Palazzo, G. F. Schwartz, D. B. Cornfield, R. L. Walker, K. Byth, C. L. Clarke, et al. Molecular Grading of Ductal Carcinoma In situ of the Breast Clin. Cancer Res., December 15, 2008; 14(24): 8244 - 8252. [Abstract] [Full Text] [PDF]

				S. Van Laere, T. Beissbarth, I. Van der Auwera, G. Van den Eynden, X. B. Trinh, H. Elst, P. Van Hummelen, P. van Dam, E. Van Marck, P. Vermeulen, et al. Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7452 - 7460. [Abstract] [Full Text] [PDF]

				C. R. Acharya and A. Potti Documenting Biospecimen Conditions in Reports of Studies--Reply JAMA, August 13, 2008; 300(6): 651 - 651. [Full Text] [PDF]

				C. K. Anders, D. S. Hsu, G. Broadwater, C. R. Acharya, J. A. Foekens, Y. Zhang, Y. Wang, P. K. Marcom, J. R. Marks, P. G. Febbo, et al. Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression J. Clin. Oncol., July 10, 2008; 26(20): 3324 - 3330. [Abstract] [Full Text] [PDF]

				E. A. Rakha, M. E. El-Sayed, A. H.S. Lee, C. W. Elston, M. J. Grainge, Z. Hodi, R. W. Blamey, and I. O. Ellis Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma J. Clin. Oncol., July 1, 2008; 26(19): 3153 - 3158. [Abstract] [Full Text] [PDF]

				X.-J. Ma, R. Salunga, S. Dahiya, W. Wang, E. Carney, V. Durbecq, A. Harris, P. Goss, C. Sotiriou, M. Erlander, et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2601 - 2608. [Abstract] [Full Text] [PDF]

				N. P. S. Crawford, J. Alsarraj, L. Lukes, R. C. Walker, J. S. Officewala, H. H. Yang, M. P. Lee, K. Ozato, and K. W. Hunter Bromodomain 4 activation predicts breast cancer survival PNAS, April 29, 2008; 105(17): 6380 - 6385. [Abstract] [Full Text] [PDF]

				C. R. Acharya, D. S. Hsu, C. K. Anders, A. Anguiano, K. H. Salter, K. S. Walters, R. C. Redman, S. A. Tuchman, C. A. Moylan, S. Mukherjee, et al. Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer JAMA, April 2, 2008; 299(13): 1574 - 1587. [Abstract] [Full Text] [PDF]

				P. Finetti, N. Cervera, E. Charafe-Jauffret, C. Chabannon, C. Charpin, M. Chaffanet, J. Jacquemier, P. Viens, D. Birnbaum, and F. Bertucci Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis Cancer Res., February 1, 2008; 68(3): 767 - 776. [Abstract] [Full Text] [PDF]

				M. Debled, G. MacGrogan, I. de Mascarel, V. Brouste, H. Bonnefoi, and L. Mauriac Expression Profiling in Breast Carcinoma: New Insights on Old Prognostic Factors? J. Clin. Oncol., September 20, 2007; 25(27): 4316 - 4317. [Full Text] [PDF]

				S. Loi, B. Haibe-Kains, C. Desmedt, and C. Sotiriou In Reply J. Clin. Oncol., September 20, 2007; 25(27): 4317 - 4318. [Full Text] [PDF]

				F. Bertucci, N. Cervera, D. Birnbaum, K. Wennmalm, L. D. Miller, J. Bergh, W. A. Woodward, A. Lucci, M. Cristofanilli, the Advanced Research Center for Micrometastatic D, et al. A Gene Signature in Breast Cancer N. Engl. J. Med., May 3, 2007; 356(18): 1887 - 1888. [Full Text] [PDF]